文献速递主动脉疾病颈动脉与弓上血管

异常锁骨下动脉的特征与外科治疗

Characterization and surgical management of aberrant subclavian arteries.
PubMed 文献 · J Vasc Surg · 2022-12-21

该回顾性研究分析了1996年至2020年间因异常锁骨下动脉(aSCA)接受手术的49例患者,其中46例有症状、3例无症状。主要终点为30天及远期死亡率,次要终点为30天并发症、移植物通畅率和再干预。结论认为aSCA的外科治疗可实现低主要并发症和死亡率,并具有优异的原发通畅率和症状缓解。

要点

  • 49例aSCA手术患者中,30天主要并发症发生率为14%,包括1例死亡。
  • 中位随访53个月,82%的患者症状完全缓解,18%的患者症状改善。
  • 原发通畅率为98%,2例(4%)在30天内因淋巴管结扎和双侧下肢筋膜切开需再干预。

核心结论

  • 异常锁骨下动脉的外科治疗可实现低主要并发症和死亡率,并具有优异的原发通畅率和症状缓解。

研究设计与样本

  • 回顾性综述,纳入1996年至2020年间因异常锁骨下动脉接受手术的症状和无症状患者,共49例(46例有症状,3例无症状)。

主要发现

  • 49例患者中,女性31例(62%),中位年龄45岁;异常右锁骨下动脉38例(78%),异常左锁骨下动脉11例(22%)。
  • 41例(84%)存在Kommerell憩室(KD),11例(22%)合并远端弓或近端降胸主动脉瘤。
  • 症状包括吞咽困难(56%)、呼吸困难(27%)、吞咽痛(20%)和上肢劳力性疲劳(16%);5例(10%)需急诊手术。
  • aSCA治疗方式:移位术32例,颈动脉至锁骨下动脉旁路11例,升主动脉至锁骨下动脉旁路6例;KD采用切除并缝合19例(39%),15例(31%)因合并主动脉疾病和/或KD治疗需远端弓或近端降胸主动脉置换,6例(12%)采用胸主动脉腔内修复术排除KD,7例(14%)仅行旁路或移位术。
  • 30天并发症包括1例死于大面积肺栓塞继发的无脉性电活动骤停;30天主要并发症(14%)包括急性呼吸衰竭3例、早期死亡1例、卒中1例、非ST段抬高型心肌梗死1例和临时透析1例;其他并发症包括乳糜胸/淋巴囊肿5例(10%)、急性肾损伤2例(4%)、肺炎2例(4%)、伤口感染2例(4%)、心房颤动2例(4%)、Horner综合征2例(4%)、下肢急性肢体缺血1例(2%)和左侧喉返神经损伤1例(2%)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Aberrant subclavian arteries (aSCAs), with or without aortic pathology, are uncommon. The purpose of the present study was to review our experience with the surgical management of aSCA. METHODS: We performed a retrospective review of patients who had undergone surgery for an aSCA between 1996 and 2020. Symptomatic and asymptomatic patients were included. The primary end points were ≤30-day and late mortality. The secondary end points were ≤30-day complications, graft patency, and reinterventions. RESULTS: A total of 46 symptomatic and 3 asymptomatic patients with aSCA had undergone surgery (31 females [62%]; median age, 45 years). An aberrant right subclavian artery was present in 38 (78%) and an aberrant left subclavian artery in 11 patients (22%). Of the 49 patients, 41 (84%) had had a Kommerell diverticulum (KD) and 11 (22%) had had a concomitant distal arch or proximal descending thoracic aortic aneurysm. Symptoms included dysphagia (56%), dyspnea (27%), odynophagia (20%), and upper extremity exertional fatigue (16%). Five patients (10%) had required emergency surgery. The aSCA had been treated by transposition in 32, a carotid to subclavian bypass in 11, and an ascending aorta to subclavian bypass in 6. The KD was treated by resection and oversewing in 19 patients (39%). Fifteen patients (31%) had required distal arch or proximal descending thoracic aortic replacement for concomitant aortic disease and/or KD treatment. Thoracic endovascular aortic repair was used to exclude the KD in six patients (12%). Seven patients (14%) had undergone only bypass or transposition. The 30-day complications included one death from pulseless electrical activity arrest secondary to massive pulmonary embolism. The 30-day major complications (14%) included acute respiratory failure in three, early mortality in one, stroke in one, non-ST-elevation myocardial infarction in one, and temporary dialysis in one patient. The other complications included chylothorax/lymphocele (n = 5; 10%), acute kidney injury (n = 2; 4%), pneumonia (n = 2; 4%), wound infection (n = 2; 4%), atrial fibrillation (n = 2; 4%), Horner syndrome (n = 2; 4%), lower extremity acute limb ischemia (n = 1; 2%), and left recurrent laryngeal nerve injury (n = 1; 2%). At a median follow-up of 53 months (range, 1-230 months), 40 patients (82%) had had complete symptom relief and 9 (18%) had experienced improvement. Six patients had died at a median of 157 months; the deaths were not procedure or aortic related. The primary patency was 98%. Reintervention at ≤30 days had been required for two patients (4%) for ligation of lymphatic vessels and bilateral lower extremity fasciotomy after proximal descending thoracic aorta replacement. One patient had required late explantation of an infected and occluded carotid to subclavian bypass graft, which was treated by cryopreserved allograft replacement. CONCLUSIONS: Surgical treatment of the aSCA can be accomplished with low major morbidity and mortality with excellent primary patency and symptom relief.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Tallarita T, Rogers RT, Bower TC, et al. Characterization and surgical management of aberrant subclavian arteries. J Vasc Surg. 2022. PMID: 36565775. doi:10.1016/j.jvs.2022.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。